Format

Send to

Choose Destination
Anticancer Res. 2016 Sep;36(9):4955-9.

Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.

Author information

1
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic kiss@mou.cz on.slaby@gmail.com.
2
Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
3
Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic.
4
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic.
5
Institute of Molecular and Translational Medicine, Faculty of Medicine and Dentistry, Palacky University Olomouc, Olomouc, Czech Republic.
6
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic Central European Institute of Technology, Masaryk University, Brno, Czech Republic.
7
Department of Oncology, Thomayer Hospital and Charles University First Faculty of Medicine, Prague, Czech Republic.
8
Department of Oncology, Motol University Hospital and Charles University Second Faculty of Medicine, Prague, Czech Republic.
9
The Fingerland Department of Pathology, Charles University Medical Faculty Hospital, Hradec Kralove, Czech Republic.
10
Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, Brno, Czech Republic Central European Institute of Technology, Masaryk University, Brno, Czech Republic kiss@mou.cz on.slaby@gmail.com.

Abstract

BACKGROUND:

In metastatic colorectal cancer (mCRC), panitumumab is generally considered to be ineffective after the progression on cetuximab therapy. However, few studies have demonstrated that a small subset of mCRC patients may benefit from panitumumab in this setting.

PATIENTS AND METHODS:

In our study, wild-type KRAS mCRC patients, enrolled into the nationwide Czech registry CORECT between January 2007 and December 2012, were screened for panitumumab therapy after progression on cetuximab.

RESULTS:

We identified 26 mCRC in the registry with well documented progression on cetuximab in combination with irinotecan-based chemotherapy (FOLFIRI or irinotecan alone) who received panitumumab monotherapy. Partial response (PR) was achieved in 3 (11.5%) patients and stable disease (SD) in 7 (26.9%) patients after 8 weeks of therapy. Thirteen (50.0%) patients had evidence of progressive disease (PD) and in 3 (11.5%) cases response was not available. Furthermore, we confirmed that higher expression levels of newly described biomarker, miR-31-5p, in tumor are significantly associated with shorter progression-free survival (PFS) in patients treated with cetuximab (p=0.038); however, we did not observe association between miR-31-5p and response to panitumumab in mCRC patients after progression on cetuximab.

CONCLUSION:

It remains possible that a subset of mCRC patients may benefit from panitumumab after progression on cetuximab.

KEYWORDS:

KRAS; Metastatic colorectal cancer; cetuximab; miR-31-5p; microRNA; panitumumab

PMID:
27630355
DOI:
10.21873/anticanres.11063
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for HighWire
Loading ...
Support Center